“This should dispel any lingering doubts about this approach,” Prof John Hardy, from the UK Dementia Research Institute, whose work led to the idea of targeting amyloid, 30 years ago, said. “Having two drugs is great for competition.”
https://healthmedicinet.com/i/new-alzheimers-drug-slows-disease-by-a-third/